ASRT stock touches 52-week low at $0.68 amid market challenges

Published 28/03/2025, 15:26
ASRT stock touches 52-week low at $0.68 amid market challenges

Assertio Therapeutics, Inc. (NASDAQ:ASRT) stock has reached a new 52-week low, dipping to $0.68, as investors navigate a tumultuous market environment. With a market capitalization of $67.5 million and a notable free cash flow yield of 39%, InvestingPro analysis suggests the stock may be undervalued at current levels. The pharmaceutical company, known for its focus on pain management treatments, has seen its shares struggle over the past year, culminating in this latest trough. The 1-year change data for the company, formerly known as Depomed , reflects a significant decline of 26.49%, underscoring the challenges faced by the firm in a competitive and rapidly evolving healthcare sector. Investors are closely monitoring the company’s performance and strategic initiatives as it attempts to recover from this low point and improve its market position. Notably, analyst price targets range from $1.75 to $3.50, suggesting potential upside. For deeper insights into ASRT’s valuation and 6 additional exclusive tips, visit InvestingPro.

In other recent news, Assertio Holdings reported its fourth-quarter 2024 earnings, with revenue surpassing expectations at $32.18 million, compared to the anticipated $28.67 million. The company also recorded a narrower-than-expected loss per share of $0.03, which was less than the forecasted $0.04. For the full year, Assertio achieved annual revenues of approximately $125 million, slightly exceeding projections. However, the company has set a more conservative revenue guidance for 2025, ranging between $108 million and $123 million, which is lower than previous expectations.

H.C. Wainwright analyst Raghuram Selvaraju adjusted Assertio’s stock price target to $3.50 from $4.00, maintaining a Buy rating. The revision comes despite the positive earnings surprise, due to a cautious outlook for 2025 amid competitive pressures and slower-than-anticipated sales growth for some products. The analyst also projects a net loss for Assertio in 2025 of $0.19 per share, which is a downward revision from the previously expected loss of $0.03 per share. Assertio’s CEO, Brendan O’Grady, highlighted the company’s transformation strategy for 2025, emphasizing potential strategic acquisitions to drive growth.

Assertio’s product sales for the year reached $120.8 million, with Rolvadon sales contributing significantly. The company anticipates modest growth for Rolvadon and double-digit growth for SYMPAZAN in 2025. Despite these positive developments, Assertio faces challenges from generic competition, particularly impacting its INDOCIN franchise. The company’s strategic focus remains on product innovation and expansion to navigate these competitive pressures.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.